Wells Fargo Healthcare Conference In Brief
This article was originally published in The Gray Sheet
Executive Summary
Orthovita: The company is in discussions with FDA regarding a 510(k) for a next-generation Vitoss bone graft substitute; it hopes to launch the device in the first quarter of 2011, Chief Financial Officer Nancy Broadbent said during a June 23 presentation at the Wells Fargo Healthcare Conference in Boston. The device will incorporate a drug that has "demonstrated positive impact on bone regeneration," she noted. Orthovita also plans to study new indications for Cortoss bone augmentation material, which was cleared last year for vertebral compression fractures, but Broadbent declined to be specific (1"The Gray Sheet" June 15, 2009). She explained that the company decided to lower the average selling price of Cortoss from $2,000 to $1,300 after the launch to better compete with existing vertebroplasty products, which cost about $950, she noted. "Our accounts have [since] grown steadily every month," she claimed